Agilent Announces USC Collaboration
Agilent Technologies has announced a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience with the aim of creating an Agilent Center of Excellence (CoE) in biomolecular characterization.
Agilent Technologies (Santa Clara, California, USA) has announced a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience with the aim of creating an Agilent Center of Excellence (CoE) in biomolecular characterization.
“Agilent’s collaboration with the Michelson Center is an excellent example of how academia and industry can work together, sharing knowledge and expertise to shorten the timeline between scientific discoveries and real-world applications,” said Darlene Solomon, senior vice president and chief technology officer for Agilent.
The center will bring researchers together from across science and engineering to work together on multidisciplinary approaches, aiming to develop improved health care through new drugs, diagnostics, and medical devices.
Key to the Agilent CoE will be a collaboration with the USC Michelson Center principal investigator Valery Fokin. The Fokin laboratory at USC focuses on chemical reactivity and biological interactions at the molecular level and will contribute to multiple collaborative drug discovery projects ranging from chemical synthesis of screening and focused libraries and biological assay implementation to the development of targeted drug delivery systems, diagnostics, and vaccines.
Additional notable contributors to this collaboration include: Steve Kay, Provost Professor of Neurology, Biomedical Engineering, and Biological Sciences; Raymond C. Stevens, Provost Professor of Biological Sciences and Chemistry; and Peter Kuhn, Dean’s Professor of Biological Sciences.
“Convergent bioscience research requires successful collaboration across multiple disciplines-a holistic approach that is central to Agilent’s view of the future,” said Solomon.
For more information, please visit www.agilent.com or https://michelson.usc.edu/
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
